UnitedHealth: Buy Like Buffett

Berkshire Hathaway has disclosed an investment exceeding $1 billion in UnitedHealth (UNH), signaling confidence despite the healthcare giant's recent share price declines and profitability headwinds. While UNH reported 13% Q2 revenue growth, profit margins contracted due to rising costs, leading to a year-over-year net profit drop. Analysts, however, anticipate a future profitability rebound for UNH, projecting potential share price gains of 50-80% by 2028 if margins recover, positioning it as an attractive long-term opportunity.

Analysis

Berkshire Hathaway's recent 13F disclosure reveals a new investment exceeding $1 billion in UnitedHealth (UNH), a significant vote of confidence in the health insurance giant amidst recent headwinds. This move comes as UNH navigates a period of share price decline and margin pressure. The company's second-quarter results highlight this dichotomy, with strong revenue growth of 13% being overshadowed by a significant year-over-year drop in net profit. This profitability decline is directly attributed to contracting margins from rising costs. However, analyst consensus points towards a future rebound, with forecasts suggesting a potential 50% to 80% appreciation in share price by 2028, contingent on the successful recovery of these margins. The current investment landscape for UNH is therefore characterized by a trade-off between near-term operational challenges and a compelling long-term upside, now endorsed by a major institutional investor.

Key Decisions for Investors

• Long-term investors should consider the current valuation as a potential entry point, given the analyst-projected upside of 50-80% by 2028 is contingent on margin recovery.
• Closely monitor UnitedHealth's upcoming quarterly reports for evidence that rising costs are being managed and that profit margins are beginning to stabilize or improve, as this is the primary catalyst for the long-term thesis.
• Investors should be prepared to tolerate short-term share price volatility, as the path to margin recovery may be uneven, making the stock more suitable for portfolios with a multi-year investment horizon.